NAD+ Metabolism, Redox Biology and Research Models
The short answer
Nicotinamide adenine dinucleotide (NAD+) is an essential cellular cofactor. Its oxidized and reduced forms, NAD+ and NADH, transfer electrons in metabolic reactions. NAD+ is also consumed by signalling enzymes including sirtuins, poly(ADP-ribose) polymerases and CD38.
NAD biology is not one simple “level.” Total tissue NAD, compartment-specific redox ratios, synthesis, salvage, consumption and downstream signalling can change differently. A finding from a precursor, genetic model or specific delivery method cannot automatically be assigned to externally supplied NAD+.
Redox chemistry
NAD+ accepts electrons to form NADH, while NADH can donate electrons in other reactions. The NAD+/NADH relationship helps connect glycolysis, mitochondrial metabolism and many dehydrogenase reactions. Cytosolic and mitochondrial pools are regulated differently and should not be treated as one uniform compartment.
NAD as a consumed substrate
Sirtuins use NAD+ during protein deacylation. PARP enzymes consume NAD+ during ADP-ribosylation associated with DNA-damage responses. CD38 and related enzymes also metabolize NAD. Changes in these pathways may alter NAD availability, but the biological consequence depends on tissue, stressor and timing.
How cells maintain NAD
Cells can synthesize NAD through de novo and Preiss–Handler pathways and can recycle nicotinamide through salvage pathways. Precursors such as nicotinamide, nicotinic acid, nicotinamide riboside and nicotinamide mononucleotide enter different parts of this network. They are not chemically identical to NAD+ and do not provide interchangeable evidence.
What research models can show
Cell culture, genetic models and animals help test how NAD synthesis or consumption affects defined endpoints. Researchers have measured mitochondrial function, metabolic flux, DNA-damage responses, inflammation and age-associated phenotypes.
A model can reveal mechanism without predicting a clinical benefit. Increasing a measured NAD-related marker also does not prove that health, performance or longevity improves.
Externally supplied NAD+ is a separate question
Studies involving oral precursors, enzyme inhibition or tissue-specific genetic changes do not establish the pharmacokinetics or effects of an externally supplied NAD+ preparation. Extracellular metabolism, transport, formulation, route and tissue exposure are separate experimental questions.
Evidence should be assigned to the exact compound and intervention studied.
Key points
- NAD+ participates in both redox reactions and enzyme signalling.
- Cellular pools are compartmentalized.
- Precursors and NAD+ are different materials.
- Biomarker increases are not clinical outcomes.
- Evidence from genetic, precursor or animal models cannot be transferred automatically to a separate NAD+ product.
What this article does not establish
This article does not establish that externally supplied NAD+ improves energy, recovery, cognition, healthy ageing or any other human outcome. It does not establish equivalence between an AURAPEP material and a cited intervention, or establish safety, effectiveness or suitability for human use.
References
- Belenky P, Bogan KL, Brenner C. NAD+ metabolism in health and disease. Trends Biochem Sci. 2007. https://pubmed.ncbi.nlm.nih.gov/17962057/
- Cantó C, Menzies KJ, Auwerx J. NAD+ metabolism and the control of energy homeostasis. Cell Metab. 2015. https://pubmed.ncbi.nlm.nih.gov/26477810/
- Srivastava S. Emerging therapeutic roles for NAD+ metabolism in mitochondrial and age-related disorders. Clin Transl Med. 2016. https://pubmed.ncbi.nlm.nih.gov/27465020/
- Covarrubias AJ, et al. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021. https://pubmed.ncbi.nlm.nih.gov/33028868/